As­traZeneca castoff draws $123M wa­ger on CX­CR2 an­tag­o­nist as Are­na lines up a buy­out op­tion

Back in 2018, James Mack­ay — then lead­ing an in­flam­ma­to­ry dis­ease group at As­traZeneca af­ter lead­ing the phar­ma gi­ant’s ac­qui­si­tion of Ardea — took in­ter­est in a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER